Sign In
NewsRadar

Search Press
Looking for press releases of a particular company? Enter company name (or keyword) here.

   


BioXell Acquires Rights from Roche to Develop BXL 628 in Additional Indications


The compound has recently completed a phase II trial in Italy for BPH. Under the new agreement, Roche has granted BioXell exclusive worldwide development rights to BXL 628 for all non-topical and non-dermatological applications.

Financial details of the agreement were not disclosed.

Dr. Francesco Sinigaglia, CEO of BioXell, said, “Extending our agreement with Roche is a significant achievement for BioXell since we believe BXL 628 is an innovative compound that may be a treatment for a number of serious urological conditions. This agreement will allow us to begin a phase IIa trial for overactive bladder conditions by the end of the year, adding the value of a second potential blockbuster to our portfolio.”


About BioXell

BioXell is a private biopharmaceutical company focusing on the discovery and development of new treatments for urological and chronic inflammatory disorders. Through its proprietary technology platform based on Vitamin D3 analogues, BioXell has identified a number of promising lead development programmes. Its pipeline includes BXL 628 for benign prostatic hyperplasia as well as compounds to treat overactive bladder and other major urological indications. In order to further exploit its Vitamin D3 platform, BioXell is also collaborating with Proskelia to develop drug candidates to cure osteoporosis and secondary hyperparathyroidism. Furthermore, based on its unique understanding of the inflammatory process and knowledge of GPCRs and TREM receptor biology, BioXell is also committed to a number of cutting-edge research projects to develop new drugs for chronic inflammatory diseases in collaboration with external partners. To date, BioXell has raised a total of over € 48 million through world-class specialised healthcare VC investors including MPM Capital, Index Ventures, AlpInvest Partners N.V. and Life Science Partners and government funding. BioXell currently employs 50 people and has sites in Milan, Italy and Nutley, NJ, USA.

More information on BioXell can be found on: www.bioxell.com

Contact:

Ms. Angela Evans
Corporate Communications
BioXell S.p.A
Via Olgettina 58
Milan, Italy
Tel: +39 02 210 49 520
Fax: +39 02 210 49 555
Email: angela.evans@bioxell.com


Publisher Contact Information:

Bioxell S.p.A.
+39 02 2104951
angela.evans@bioxell.com

Company profile of Bioxell S.p.A.
Past press releases of Bioxell S.p.A..

Data


27,147
Tech investments
From our Online Data Service
17,523
VC-backed companies
From our Radar


Recent Deals


DATEAMOUNTSECTOR
Nov 25€24.0MInternet commerce
Jul 23€23.0MArtificial Intelligence
Jul 22€20.0MKnowledge management
Jul 5€110.0MOther Biotechnology & Healthcare
Jul 5€13.0MInternet services
Jul 3€3.7MMedical devices
Jul 3€27.0MPayment software

For information on Europe's most extensive database on technology funding click here!

Events



Press Releases


May 28
Identiq
identiq raises $5m seed, launches privacy-first identity validation...

Apr 29
Nethone
nethone raised over $1 million from innovation nest

Mar 31
CompPair
the fit allocates chf 100'000 to comppair technologies

Jan 29
Yumpingo
yumpingo raises $10m to transform guest experiences in restaurants

Oct 1
The Link App
the link app launches version 2.0





About usContact usLegal Information
Copyright © 1999-2019
Emerging Technology Research Europe Inc. All rights reserved.